Pieter Evenepoel, Kristien Daenen, Bert Bammens, Kathleen Claes, Björn Meijers, Maarten Naesens, Ben Sprangers, Dirk Kuypers, Eveline Lerut
BACKGROUND: Experimental data indicate that microscopic calcium phosphate deposition in the kidney (nephrocalcinosis) may accelerate progression of chronic kidney disease (CKD). Data on the prevalence, risk factors and implications of nephrocalcinosis in CKD patients are scarce. A mineral metabolism disorder could play an important pathogenetic role, as suggested by recent protocol biopsy findings in incident renal transplant recipients. METHODS: Kidney biopsy cylinders of CKD patients, collected between January 1989 and December 2007, were screened for the presence of nephrocalcinosis...
May 2015: Nephrology, Dialysis, Transplantation
Marcello Tonelli, Christoph Wanner
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all adults and children with chronic kidney disease (CKD). All forms of CKD are included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients). METHODS: The KDIGO Lipid Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team...
February 4, 2014: Annals of Internal Medicine
Rodrigo A de Oliveira, Fellype C Barreto, Monique Mendes, Luciene M dos Reis, João Henrique Castro, Zita Maria L Britto, Igor D B Marques, Aluizio B Carvalho, Rosa M Moysés, Vanda Jorgetti
Chronic kidney disease--mineral bone disorder (CKD-MBD) is a complex syndrome influenced by various factors, such as age, CKD etiology, uremic toxins, and dialysis modality. Although extensively studied in hemodialysis (HD) patients, only a few studies exist for peritoneal dialysis (PD) patients. Since most of these older studies contain no bone biopsy data, we studied the pattern of renal osteodystrophy in 41 prevalent PD patients. The most common presentation was adynamic bone disease (49%). There was a significant inverse association between serum sclerostin (a Wnt/β-catenin pathway inhibitor that decreases osteoblast action and bone formation) and the bone formation rate...
May 2015: Kidney International
Aníbal Ferreira, João Miguel Frazão, Marie-Claude Monier-Faugere, Célia Gil, José Galvao, Carlos Oliveira, Jorge Baldaia, Ilidio Rodrigues, Carla Santos, Silvia Ribeiro, Regula Mueller Hoenger, Ajay Duggal, Hartmut H Malluche
Disturbances in mineral metabolism play a central role in the development of renal bone disease. In a 54-wk, randomized, open-label study, 119 hemodialysis patients were enrolled to compare the effects of sevelamer hydrochloride and calcium carbonate on bone. Biopsy-proven adynamic bone disease was the most frequent bone abnormality at baseline (59%). Serum phosphorus, calcium, and intact parathyroid hormone were well controlled in both groups, although calcium was consistently lower and intact parathyroid hormone higher among patients who were randomly assigned to sevelamer...
February 2008: Journal of the American Society of Nephrology: JASN
Biagio Di Iorio, Donald Molony, Cynthia Bell, Emanuele Cucciniello, Vincenzo Bellizzi, Domenico Russo, Antonio Bellasi
BACKGROUND: Whether the use of sevelamer rather than a calcium-containing phosphate binder improves cardiovascular (CV) survival in patients receiving dialysis remains to be elucidated. STUDY DESIGN: Open-label randomized controlled trial with parallel groups. SETTINGS & PARTICIPANTS: 466 incident hemodialysis patients recruited from 18 centers in Italy. INTERVENTION: Study participants were randomly assigned in a 1:1 fashion to receive either sevelamer or a calcium-containing phosphate binder (although not required by the protocol, all patients in this group received calcium carbonate) for 24 months...
October 2013: American Journal of Kidney Diseases
Meteb M AlBugami, Jo-Anne Wilson, James R Clarke, Steven D Soroka
BACKGROUND: Calcific uremic arteriolopathy (CUA) is a rare but serious disorder affecting 4% of dialysis patients. Intravenous sodium thiosulfate (IV STS) has been shown as an effective treatment. In Canada, the average cost of IV STS is about CAD 12,000 per month, while the cost of compounded oral STS is CAD 45 per month. METHODS: Prospective cohort where all patients diagnosed with CUA during the year 2011 were included. They were treated initially with IV STS...
2013: American Journal of Nephrology
Neal X Chen, Kalisha O'Neill, Nader Kassis Akl, Sharon M Moe
BACKGROUND: Calcification can occur in fat in multiple clinical conditions including in the dermis, breasts and in the abdomen in calciphylaxis. All of these are more common in patients with advanced kidney disease. Clinically, hyperphosphatemia and obesity are risk factors. Thus we tested the hypothesis that adipocytes can calcify in the presence of elevated phosphorus and/or that adipocytes exposed to phosphorus can induce vascular smooth muscle cell (VSMC) calcification. METHODS: 3T3-L1 preadipocytes were induced into mature adipocytes and then treated with media containing high phosphorus...
June 20, 2014: Biochemical and Biophysical Research Communications
Corisande Baldwin, Myriam Farah, Marianna Leung, Paul Taylor, Ronald Werb, Mercedeh Kiaii, Adeera Levin
Calcific uremic arteriolopathy (calciphylaxis) is a devastating but rare complication seen predominantly in dialysis patients that often is fatal. Because of the rarity of the disease and the multifactorial nature of its cause, no clinical trials have been conducted to date to determine the best therapy for the condition. We report a case series of 7 patients at a single institution in whom a systematic multi-interventional treatment strategy was implemented, consisting of trigger-agent cessation (calcium-based phosphate binders, alphacalcidol, and warfarin), wound management, and antibiotic therapy, supplemented by intensified hemodialysis (4 hours daily for 7 days followed by 5-6 times weekly), intravenous sodium thiosulfate (12...
December 2011: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Hermann Salmhofer, Michael Franzen, Wolfgang Hitzl, Josef Koller, Bernhard Kreymann, Falko Fend, Cornelia Hauser-Kronberger, Uwe Heemann, Frieder Berr, Christoph Schmaderer
BACKGROUND: Calciphylaxis is a rare, yet life-threatening disease mainly occurring in dialysis patients. Traditional options of treatment remain unsatisfactory. METHODS: Here we present a novel, combined approach, treating calciphylaxis with IV sodium thiosulfate, cinacalcet and sevelamer. In a case series five hemodialysis patients, have been successfully treated with this regimen. Treatment and survival data were analyzed using descriptive statistics. RESULTS: In all patients, a rapid decrease in pain, improvement of general condition and wound healing within six months occurred...
2013: Kidney & Blood Pressure Research
Sagar U Nigwekar, Craig A Solid, Elizabeth Ankers, Rajeev Malhotra, William Eggert, Alexander Turchin, Ravi I Thadhani, Charles A Herzog
BACKGROUND: Calciphylaxis, a rare disease seen in chronic dialysis patients, is associated with significant morbidity and mortality. As is the case with other rare diseases, the precise epidemiology of calciphylaxis remains unknown. Absence of a unique International Classification of Diseases (ICD) code impedes its identification in large administrative databases such as the United States Renal Data System (USRDS) and hinders patient-oriented research. This study was designed to develop an algorithm to accurately identify cases of calciphylaxis and to examine its incidence and mortality...
August 2014: Journal of General Internal Medicine
Chetan Vedvyas, Laura S Winterfield, Ruth Ann Vleugels
Calciphylaxis, also known as calcific uremic arteriolopathy, is a cutaneous ischemic small vessel vasculopathy seen in 1 to 4% of patients with chronic kidney disease on hemodialysis. It is associated with extreme pain and a 60 to 80% mortality rate in the setting of few and frequently ineffective therapeutic options, although this may be changing based on reports of success with newer therapies.
December 2012: Journal of the American Academy of Dermatology
Emanuel Zitt, Matthias König, Andreas Vychytil, Martin Auinger, Manfred Wallner, Gernot Lingenhel, Gernot Schilcher, Michael Rudnicki, Hermann Salmhofer, Karl Lhotta
BACKGROUND: Calciphylaxis is a life-threatening complication in patients with end-stage renal disease (ESRD). No established therapy exists so far. The aim of the present study was to determine the therapeutic response to a multi-interventional treatment regimen with consistent use of sodium thiosulphate (STS) in an Austrian cohort of calciphylaxis patients. METHODS: We retrospectively collected demographic, clinical and laboratory data on 27 calciphylaxis patients treated with STS at seven Austrian dialysis centres between June 2004 and November 2010...
May 2013: Nephrology, Dialysis, Transplantation
Matsuhiko Hayashi, Ichiro Takamatsu, Yoshihiko Kanno, Tadashi Yoshida, Takayuki Abe, Yuji Sato
BACKGROUND: Calciphylaxis, also called calcific uremic arteriolopathy, is a rare and often fatal complication of end-stage renal disease and is characterized by painful skin ulceration, necrosis, medial calcification and intimal proliferation of small arteries. Studies in western countries have reported incidences ranging from 1 to 4% in chronic hemodialysis patients. Since no systematic studies of calciphylaxis have ever been performed in Japan, we conducted a nationwide survey and a case-control study to identify the characteristics of calciphylaxis in the Japanese dialysis population...
April 2012: Nephrology, Dialysis, Transplantation
Zhihong Liu, Haitao Zhang, Zhangsuo Liu, Changying Xing, Ping Fu, Zhaohui Ni, Jianghua Chen, Hongli Lin, Fuyou Liu, Yongcheng He, Yani He, Lining Miao, Nan Chen, Ying Li, Yong Gu, Wei Shi, Weixin Hu, Zhengzhao Liu, Hao Bao, Caihong Zeng, Minlin Zhou
BACKGROUND: Treatment of lupus nephritis (LN) remains challenging. OBJECTIVE: To assess the efficacy and safety of a multitarget therapy consisting of tacrolimus, mycophenolate mofetil, and steroid compared with intravenous cyclophosphamide and steroid as induction therapy for LN. DESIGN: 24-week randomized, open-label, multicenter study. ( NCT00876616). SETTING: 26 renal centers in China. PATIENTS: Adults (aged 18 to 65 years) with biopsy-proven LN...
January 6, 2015: Annals of Internal Medicine
Takahito Moriyama, Mitsuyo Itabashi, Takashi Takei, Hiroshi Kataoka, Masayo Sato, Ari Shimizu, Yuko Iwabuchi, Miki Nishida, Keiko Uchida, Kosaku Nitta
BACKGROUND: High uric acid level is a known risk factor for deterioration of renal function in chronic kidney disease (CKD), but its influence on the progression of IgA nephropathy (IgAN) remains unclear. METHODS: Adult IgAN patients (n = 611) were classified according to CKD stage. Renal survival rates and clinical and histological findings were compared between patients with high (H-UA) and normal (N-UA) uric acid levels in different CKD stages. RESULTS: The proportion of patients with H-UA increased significantly with increasing CKD stage (stage G1, 12...
August 2015: Journal of Nephrology
Genyang Cheng, Dongwei Liu, Peter Margetts, Limin Liu, Zhanzheng Zhao, Zhangsuo Liu, Lin Tang, Yudong Fang, Haijian Li, Yuanyuan Guo, Fengmei Chen, Fengxun Liu
AIM: The current standard treatment for IgA nephropathy relies on steroid and/or immunosuppressive therapy and angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB). This study examines the benefits and safety of combining valsartan with clopidogrel and leflunomide as a treatment for progressive IgA nephropathy. METHODS: Patients with primary IgA nephropathy, confirmed by renal biopsy, were recruited for this study. Patients were separated into four groups (n = 42 each) after 2 months of run-in period of valsartan treatment...
February 2015: Nephrology
Jihua Tian, Yanhong Wang, Xinyan Liu, Xiaoshuang Zhou, Rongshan Li
IgA nephropathy is the most frequent type of glomerulonephritis worldwide. The role of cell cycle regulation in the pathogenesis of IgA nephropathy has been studied. The present study was designed to explore whether rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms. After establishing an IgA nephropathy model, rats were randomly divided into four groups. Coomassie Brilliant Blue was used to measure the 24-h urinary protein levels. Renal function was determined using an autoanalyzer. Proliferation was assayed via Proliferating Cell Nuclear Antigen (PCNA) immunohistochemistry...
July 2015: Experimental Biology and Medicine
Yan Ding, Mary E Choi
Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide, and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Increasing prevalence of diabetes has made the need for effective treatment of DN critical and thereby identifying new therapeutic targets to improve clinical management. Autophagy is a highly conserved 'self-eating' pathway by which cells degrade and recycle macromolecules and organelles. Autophagy serves as an essential mechanism to maintain homeostasis of glomeruli and tubules, and plays important roles in human health and diseases...
January 2015: Journal of Endocrinology
Josef Coresh, Tanvir Chowdhury Turin, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Lawrence J Appel, Hisatomi Arima, Steven J Chadban, Massimo Cirillo, Ognjenka Djurdjev, Jamie A Green, Gunnar H Heine, Lesley A Inker, Fujiko Irie, Areef Ishani, Joachim H Ix, Csaba P Kovesdy, Angharad Marks, Takayoshi Ohkubo, Varda Shalev, Anoop Shankar, Chi Pang Wen, Paul E de Jong, Kunitoshi Iseki, Benedicte Stengel, Ron T Gansevoort, Andrew S Levey
IMPORTANCE: The established chronic kidney disease (CKD) progression end point of end-stage renal disease (ESRD) or a doubling of serum creatinine concentration (corresponding to a change in estimated glomerular filtration rate [GFR] of −57% or greater) is a late event. OBJECTIVE: To characterize the association of decline in estimated GFR with subsequent progression to ESRD with implications for using lesser declines in estimated GFR as potential alternative end points for CKD progression...
June 25, 2014: JAMA
Mohammad Reza Ardalan
No abstract text is available yet for this article.
2013: Journal of Renal Injury Prevention
2014-10-27 05:22:15
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"